Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Bioseparations, Plasma-derived Therapeutics, and Small Molecule Therapeutics. The Bioseparations segment offers prometic's core bioseparation technologies and products. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The Small Molecule Therapeutics segment manufactures drug candidates such as PBI-4050, PBI-4547, and PBI-4425. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.